Investigators at Dana-Farber Cancer Institute are opening a new clinical trial to evaluate a novel type of immune cellular ...

as well as a 2020 deal with Australian biotech oNKo-innate to find targets that boost NK cell activity against tumours. Along with the upfront payment, Dragonfly is in line for undisclosed opt-in ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

inhibits the anti-tumor activity of natural killer (NK) cells through its receptor. They also proposed a new immunotherapy strategy based on receptor antagonism. Their study was published in ...

Risk - "Early" is often a massive weakness Being in phase 1 studies makes for an important milestone, but without a lot of clear evidence about the activity and safety of these NK cell therapies ...

inhibits the anti-tumor activity of natural killer (NK) cells through its receptor. They also proposed a new immunotherapy strategy based on receptor antagonism. Their study was published in ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today ...

PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) is set to showcase groundbreaking advancements in its iPSC-derived ...

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Fate Therapeutics Inc ( (FATE) ) has released its Q3 earnings. Here is a breakdown of the information Fate Therapeutics Inc presented to its ...